Skip to main content
Article thumbnail
Location of Repository

Recombinant Human Leptin Treatment Does Not Improve Insulin Action in Obese Subjects With Type 2 Diabetes

By Bettina Mittendorfer, Jeffrey F. Horowitz, Alex M. DePaoli, Mark A. McCamish, Bruce W. Patterson and Samuel Klein
Topics: Metabolism
Publisher: American Diabetes Association
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1998). A leptin dose-response study in obese (ob/ob) and lean (+/?) mice.
  2. Analysis of paradoxical observations on the association between leptin and insulin resistance.
  3. (2005). Author Group. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes Obes Metab
  4. (2008). Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients.
  5. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction.
  6. (1997). Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin Pharmacol Ther
  7. Efficacy and safety of leptinreplacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.
  8. (1994). Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
  9. (2001). Leptin administration improves skeletal muscle insulin responsiveness in diet-induced insulin-resistant rats.
  10. (2009). Leptin at 14 y of age: an ongoing story.
  11. Leptin deficiency causes insulin resistance induced by uncontrolled diabetes.
  12. Leptin impairs insulin signaling in rat adipocytes.
  13. (1997). Leptin impairs metabolic actions of insulin in isolated rat adipocytes.
  14. (1999). Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy.
  15. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
  16. Leptin-replacement therapy for lipodystrophy.
  17. (2009). Leptin: a pivotal regulator of human energy homeostasis.
  18. (2011). Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women.
  19. (1992). Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes
  20. (2010). Obesity and insulin resistance-related changes in the expression of lipogenic and lipolytic genes in morbidly obese subjects. Obes Surg
  21. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptindeficient adults.
  22. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
  23. (1996). Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes
  24. Reproducibility of glucose, fatty acid and VLDL kinetics and multi-organ insulin sensitivity in obese subjects with nonalcoholic fatty liver disease. Int J Obes.
  25. (1996). Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice.
  26. The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects.
  27. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.